Acute Ischemic Stroke Clinical Trial
Official title:
Safety, Performance and Usability of BALT Medical Devices: The EVIDENCE Post Marketing Clinical Follow-up Platform. An International, Multicenter, Prospective, and Retrospective Data Collection
BALT has designed an electronic platform to continue collecting clinical data as part of the post-marketing clinical follow-up of its devices. This platform is purely exploratory, without hierarchical order of the objectives and associated outcomes.
Status | Recruiting |
Enrollment | 10000 |
Est. completion date | October 2041 |
Est. primary completion date | June 2041 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years and older |
Eligibility | Inclusion Criteria: - Provision of a signed, written and dated informed consent or non-opposition (where applicable) Exclusion Criteria - Device(s) used in multiple procedures (two, or more, pathologies treated during the same procedure) - Contra-indications of each device as described in the instructions for use. |
Country | Name | City | State |
---|---|---|---|
France | CHU Angers | Angers | |
France | CHU Grenoble Alpes | La Tronche | |
France | Hôpital Roger Salengro | Lille | |
France | Chu Tours | Tours | |
Spain | Hospital Clinico Universitario San Carlos | Madrid | |
Spain | Hospital: Fundacion Jimenez Diaz | Madrid | |
Spain | Hospital: Puerta de Hierro | Madrid | |
Spain | Unversitario Central de Asturias | Oviedo | |
Spain | Hospital Universitario Marqués de Valdecilla (HUMV) | Santander | |
Spain | Hospital Universitario Miguel Servet | Zaragoza |
Lead Sponsor | Collaborator |
---|---|
Balt Extrusion |
France, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of occurrence of device-specific safety indicator(s). | Specific outcomes will be adapted accordingly for each device family since the intended use will vary according to the device families. | From the procedure to 12 months post-procedure depending on the device family. | |
Primary | Rate of devices achieving its intended use. | Specific outcomes will be adapted accordingly for each device family since the intended use will vary according to the device families. | From the procedure to 12 months post-procedure depending on the device family. | |
Primary | Rate of devices achieving its specific performance indicator(s). | Specific outcomes will be adapted accordingly for each device family since the intended use will vary according to the device families. | From the procedure to 12 months post-procedure depending on the device family. | |
Primary | Rate of devices in each category of the usability scale (Likert-type scale) for each usability indicator | Qualitative measurement of usability for each usability indicator (i.e., good, well adapted, fairly adapted, bad). Specific outcomes will be adapted accordingly for each device family since the intended use will vary according to the device families. | From the procedure to 12 months post-procedure depending on the device family. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06113848 -
Adjunctive Use of Intra-Arterial TNK and Albumin Following Thrombectomy
|
Phase 3 | |
Completed |
NCT04069546 -
The Efficacy of Remote Ischemic Conditioning on Stroke-induced Immunodeficiency
|
N/A | |
Active, not recruiting |
NCT05700097 -
Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy
|
Phase 2 | |
Recruiting |
NCT06058130 -
Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis
|
N/A | |
Recruiting |
NCT04415164 -
Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke
|
Phase 4 | |
Recruiting |
NCT05363397 -
Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke
|
Phase 2 | |
Completed |
NCT05429658 -
Single Arm Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System
|
N/A | |
Recruiting |
NCT05390580 -
Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct
|
N/A | |
Enrolling by invitation |
NCT05515393 -
A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke
|
Phase 2 | |
Active, not recruiting |
NCT05070260 -
ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo
|
Phase 2/Phase 3 | |
Terminated |
NCT05547412 -
Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke
|
||
Completed |
NCT03366818 -
New Stent Retriever, VERSI System for AIS
|
N/A | |
Not yet recruiting |
NCT06437431 -
Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06040476 -
Human Umbilical Cord Blood Infusion in Patients With Acute Ischemic Stroke (AIS)
|
Phase 2 | |
Not yet recruiting |
NCT05293080 -
Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE
|
Phase 3 | |
Completed |
NCT02223273 -
Brazilian Intervention to Increase Evidence Usage in Practice - Stroke (BRIDGE-Stroke)
|
N/A | |
Completed |
NCT02586233 -
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT01594190 -
Physical Activity Immediately After Acute Cerebral Ischemia
|
N/A | |
Terminated |
NCT01694381 -
Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor
|
Early Phase 1 | |
Completed |
NCT01120301 -
Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3)
|
Phase 3 |